Immuron Limited (NASDAQ: IMRN) has announced funding of a new research agreement with the United States Department of Defense. This agreement, titled “Biologics License Application (BLA) of a therapeutic Bovine Immunoglobulin supplement targeting Travelers’ Diarrhea caused by Enterotoxigenic Escherichia Coli (ETEC)” is focused on testing and confirming the efficacy of a single dose regimen of Travelan. Travelan is a controlled human infection model clinical study using the enterotoxigenic Escherichia coli (ETEC) strain H10407.
“This new project expands our clinical development program and represents the first of several significant clinical trials which the Company expects to undertake with the US Military in 2022. The NMRC also plans to clinically evaluate the protective efficacy of our new oral therapeutic targeting Campylobacter and ETEC this year in two controlled human infection-model clinical trials, with one trial focusing on the ability of the hyperimmune product to protect volunteers against moderate to severe campylobacteriosis, and the second trial focusing on ETEC infections,” said Dr. Jerry Kanellos, CEO of Immuron. “The new funding is testament to the value proposition our hyperimmune bovine polyclonal colostrum technology offers to benefit the US Military as well as the civilian international travelling population.”